No Data
No Data
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP)
Express News | Cantor Fitzgerald Reiterates Overweight on Akero Therapeutics
CCORF Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $56
CCORF analyst Edward Nash maintains $Akero Therapeutics(AKRO.US)$ with a buy rating, and maintains the target price at $56.According to TipRanks data, the analyst has a success rate of 40.9% and a tot
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46
Morgan Stanley analyst Michael Ulz maintains $Akero Therapeutics(AKRO.US)$ with a buy rating, and maintains the target price at $46.According to TipRanks data, the analyst has a success rate of 40.8%
Akero Therapeutics Initiated at Outperform by Wolfe Research
Akero Therapeutics Initiated at Outperform by Wolfe Research
Express News | Wolfe Research Initiates Coverage On Akero Therapeutics With Outperform Rating